<DOC>
	<DOCNO>NCT00914966</DOCNO>
	<brief_summary>The objective study : 1 . To assess safety tolerability escalate dos CINRYZE . 2 . To assess effect escalate dose algorithm CINRYZE hereditary angioedema ( HAE ) attack rate . 3 . To assess immunogenicity CINRYZE .</brief_summary>
	<brief_title>A Study Evaluate Safety Effect Escalating Doses CINRYZE</brief_title>
	<detailed_description>Qualifying subject enter 3-step dose escalation algorithm : - Step 1 : 1500 Units twice per week ( start dose regimen subject study ) - Step 2 : 2000 Units twice per week - Step 3 : 2500 Units twice per week Each step consist 12 week safety monitoring , follow calculation average monthly angioedema attack rate base subject report angioedema symptom ( regardless intensity ) actual duration therapy step . If subject deem `` success '' give step investigator medical monitor determine safe subject continue dose , subject enter 3 month follow-up period dose level continued safety monitoring . The subject could re-enter study purpose dose escalation follow-up period . If subject deem `` success , '' subject initiate next high step dose escalation algorithm provide investigator medical monitor agree dose escalation appropriate . If end Step 3 ( 2500 Units ) , subject deem `` success , '' Week 12 visit represent study completion subject refer physician manages HAE care .</detailed_description>
	<mesh_term>Angioedema</mesh_term>
	<mesh_term>Angioedemas , Hereditary</mesh_term>
	<mesh_term>Complement C1 Inactivator Proteins</mesh_term>
	<mesh_term>Complement C1 Inhibitor Protein</mesh_term>
	<criteria>To eligible protocol , subject must : 1 . Be ≥6 year age ≥25 kg body weight . 2 . Have confirm diagnosis HAE document history swell face , extremity , gastrointestinal tract , genitalia , larynx history least one following : C1 INH gene mutation C4 level lower limit reference range C1 INH antigen level lower limit reference range Functional C1 INH level lower limit reference range Family history HAE ( i.e. , grandparent , parent , sibling ) 3 . Have history &gt; 1.0 HAE attack per month ( average ) severity 3 consecutive month prior screen receive recommend CINRYZE dose 1000 Units every 3 4 day via intravenous injection . 4 . If adult , informed nature study provide write informed consent studyspecific procedure perform . OR 5 . If child , parent/legal guardian willing able provide write informed consent child participate study ( assent child appropriate ) . To eligible protocol , subject must : 1 . Have , determine investigator and/or sponsor 's medical monitor , surgical medical condition could interfere administration study drug interpretation study result . 2 . Have history abnormal blood clot coagulopathy . 3 . Be take prescription anticoagulant medication . 4 . Have history allergic reaction CINRYZE blood product . 5 . Have participate investigational drug study within past 30 day ( CINRYZE protocol ) . 6 . Have receive blood product ( CINRYZE ) within 60 day prior screen . 7 . Have follow laboratory value screen : Hemoglobin &lt; 8 g/dL White blood cell count &lt; 2 x 10^9/L &gt; 20 x 10^9/L Platelet count &lt; 50 x 10^9/L &gt; 400 x 10^9/L Serum aspartate aminotransferase ( AST ) and/or alanine aminotransferase ( ALT ) &gt; 2.0 x upper limit normal Blood urea nitrogen and/or creatinine &gt; 2.0 x upper limit normal 8 . Be pregnant breastfeeding .</criteria>
	<gender>All</gender>
	<minimum_age>6 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>March 2014</verification_date>
</DOC>